Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.
Shirong ZhangWen-Xian WangChun-Wei XuYong-Chang ZhangXiuyu CaiQian WangZhengbo SongZiming LiJinpu YuWen-Zhao ZhongZhijie WangJingjing LiuAnwen LiuWen LiPing ZhanHongbing LiuTangfeng LvLi-Yun MiaoLingfeng MinGen LinLong HuangJingping YuanZhansheng JiangXingxiang PuChuangzhou RaoDongqing LvZongyang YuXiaoyan LiChuanhao TangCheng-Zhi ZhouJunping ZhangHui GuoQian ChuRui MengXuewen LiuJingxun WuJin ZhouZhengfei ZhuWeiwei PanXiaowei DongFei PangKai WangChao YaoGuomin LinSite LiZhi YangJiancheng LuoHongtao JiaXiuqing NieLiping WangYoucai ZhuXiao HuYanru XieXinqing LinJing CaiYang XiaHuijing FengLin WangYingying DuWang YaoXuefei ShiXiaomin NiuDongmei YuanYanwen YaoJing KangJiatao ZhangChao ZhangWenbin GaoJianhui HuangYinbin ZhangPingli SunHong WangMingxiang YeDong WangZhaofeng WangBing WanDonglai LvGenhua YuLin ShiYuanli XiaFeng GaoXiaochen ZhangTao XuWei ZhouHaixia WangZhefeng LiuNong YangLin WuQiming WangGuansong WangZhuan HongJiandong WangMeiyu FangYong FangYiping ZhangYong SongShenglin MaWenfeng FangYuanzhi LuPublished in: Thoracic cancer (2022)
Human epidermal growth factor receptor 2 (HER2) possesses tyrosine kinase activity and participates in cell growth, differentiation and migration, and survival. Its alterations, mainly including mutations, amplifications, and overexpression are associated with poor prognosis and are one of the major drivers in non-small cell lung cancer (NSCLC). Several clinical trials had been investigating on the treatments of HER2-altered NSCLC, including conventional chemotherapy, programmed death 1 (PD-1) inhibitors, tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs), however, the results were either disappointing or encouraging, but inconsistent. Trastuzumab deruxtecan (T-DXd) was recently approved by the Food and Drug Administration as the first targeted agent for treating HER2-mutant NSCLC. Effective screening of patients is the key to the clinical application of HER2-targeted agents such as TKIs and ADCs. Various testing methods are nowadays available, including polymerase chain reaction (PCR), next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), etc. Each method has its pros and cons and should be reasonably assigned to appropriate patients for diagnosis and guiding treatment decisions. To help standardize the clinical workflow, our expert group reached a consensus on the clinical management of HER2-altered NSCLC, focusing on the diagnosis and treatment strategies.
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- advanced non small cell lung cancer
- small cell lung cancer
- poor prognosis
- end stage renal disease
- clinical trial
- ejection fraction
- chronic kidney disease
- newly diagnosed
- drug administration
- peritoneal dialysis
- long non coding rna
- endothelial cells
- cancer therapy
- squamous cell carcinoma
- randomized controlled trial
- cell proliferation
- transcription factor
- patient reported outcomes
- dna methylation
- risk assessment
- gene expression
- climate change
- genome wide
- copy number
- quantum dots
- phase ii
- open label
- energy transfer
- induced pluripotent stem cells